Jabbour EJ, et al. - Inotuzumab ozogamicin (InO) has demonstrated efficacy and tolerability in patients aged 18 to 78 years with relapsed/refractory acute lymphoblastic leukemia (ALL) in the INO-VATE trial. In this subset analysis to compare the efficacy and safety of InO in younger and older patients, it was shown that older patients with relapsed/refractory ALL tolerated InO. Additionally, despite affording longer overall survival for younger patients vs older patients, InO showed high response rates with similar duration of remission in the 2 age groups.